资讯
Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer
Not intended for UK-, US- or Canada-based media
DARMSTADT, Germany -- (BUSINESS WIRE) --
Merck, a leading science and technology company, today announced the discontinuation of the Phase III rando...